Summary
- Main use
- Improvement of hypocalcemia in patients undergoing chronic renal dialysis and renal osteodystrophy
- Who receives it
- Adults
- Adult administration
- The appropriate dose of this drug should be carefully determined for each patient. ○ The recommended initial regimen/dose of this drug is calcitriol 0.5 ㎍ 3 times weekly (approximately 0.01㎍ per kg body weight), administered on alternate days. This drug may be administered as an IV bolus through the catheter at the end of hemodialysis. If a satisfactory response in biochemical test results and clinical symptoms is not achieved, increase the dose by 0.25∼0.50 ㎍ at intervals of 2∼4 weeks. Most hemodialysis patients respond to doses of 0.5∼3.0 ㎍ 3 times weekly (0.01∼0.05 ㎍/kg body weight). ○ Precautions related to administration 1) During the titration period for dose determination, measure serum calcium and phosphorus levels at least twice weekly. However, if the serum calcium level exceeds the upper limit of the reference range by 0.5 mg/dL, increase the frequency of measurement separately (at least once weekly) and administer cautiously, considering dose reduction. If the serum calcium level exceeds the upper limit of the reference range by 1 mg/dL, discontinue treatment immediately. After confirming that the serum calcium level has returned to the reference range during the interruption, resume treatment, considering dose reduction with reference to the dose used before the interruption. In patients with hypoalbuminemia (serum albumin < 4.0 g/dL), use the corrected value as an indicator. - Calculation of corrected calcium level: Corrected calcium level (mg/dL) = serum calcium level (mg/dL) - serum albumin level (g/dL) + 4.0 2) Ultimately, it is preferable to reduce the dose according to the decrease in parathyroid hormone (PTH) levels in response to treatment (hypercalcemia is likely to occur when PTH is excessively reduced). The recommended dose adjustment method is as follows. PTH level Dose Unchanged or slightly increased Increase dose <30% decrease Increase dose >30%, <60% decrease Continue current dose >60% decrease Reduce dose 1.5~3 times the upper limit of normal Continue current dose
Ingredients
- Manufacturer
- Yuyu Pharmaceutical Co., Ltd.
Efficacy & effects
Improvement of hypocalcemia in patients undergoing chronic renal dialysis and renal osteodystrophy
- Hypocalcemia
- elevated parathyroid hormone levels
- renal osteodystrophy
View approved original textHide original text
This medication is used to manage hypocalcemia occurring in chronic renal dialysis patients and to significantly reduce elevated parathyroid hormone levels, thereby improving renal osteodystrophy.
How it is given
Adult administration
The appropriate dose of this drug should be carefully determined for each patient. ○ The recommended initial regimen/dose of this drug is calcitriol 0.5 ㎍ 3 times weekly (approximately 0.01㎍ per kg body weight), administered on alternate days. This drug may be administered as an IV bolus through the catheter at the end of hemodialysis. If a satisfactory response in biochemical test results and clinical symptoms is not achieved, increase the dose by 0.25∼0.50 ㎍ at intervals of 2∼4 weeks. Most hemodialysis patients respond to doses of 0.5∼3.0 ㎍ 3 times weekly (0.01∼0.05 ㎍/kg body weight). ○ Precautions related to administration 1) During the titration period for dose determination, measure serum calcium and phosphorus levels at least twice weekly. However, if the serum calcium level exceeds the upper limit of the reference range by 0.5 mg/dL, increase the frequency of measurement separately (at least once weekly) and administer cautiously, considering dose reduction. If the serum calcium level exceeds the upper limit of the reference range by 1 mg/dL, discontinue treatment immediately. After confirming that the serum calcium level has returned to the reference range during the interruption, resume treatment, considering dose reduction with reference to the dose used before the interruption. In patients with hypoalbuminemia (serum albumin < 4.0 g/dL), use the corrected value as an indicator. - Calculation of corrected calcium level: Corrected calcium level (mg/dL) = serum calcium level (mg/dL) - serum albumin level (g/dL) + 4.0 2) Ultimately, it is preferable to reduce the dose according to the decrease in parathyroid hormone (PTH) levels in response to treatment (hypercalcemia is likely to occur when PTH is excessively reduced). The recommended dose adjustment method is as follows. PTH level Dose Unchanged or slightly increased Increase dose <30% decrease Increase dose >30%, <60% decrease Continue current dose >60% decrease Reduce dose 1.5~3 times the upper limit of normal Continue current dose
Precautions
Care should be taken to cut the glass ampoule carefully to avoid glass fragments when using an ampoule made of glass. Extra caution is required when used by children or the elderly. This medication should not be used in patients who are allergic to this drug or its ingredients or those who have hypercalcemia. Additionally, patients showing symptoms of vitamin D overdose should not be administered this medication. Women who are pregnant or breastfeeding should use this drug cautiously, considering the potential effects on the fetus or infant. Rarely, serious allergic reactions or redness and pain at the injection site may occur. In cases of overdose, various symptoms such as digestive disorders, neurological issues, cardiac problems, or skeletal pain may occur, so caution is required. To enhance treatment efficacy, patients should consume adequate calcium daily and regularly check calcium intake and blood calcium levels. In cases of overdose, dosing should be stopped immediately, and periodic checks of blood calcium levels should be conducted. This drug may interact with certain medications, so if other medications are being taken, consultation with a doctor or pharmacist is necessary. Caution is especially needed when using medications containing magnesium antacids, cardiac drugs, and anticonvulsants. During pregnancy or lactation, the use of this drug may pose risks to the fetus or infant, and should only be used when absolutely necessary. It is advisable to avoid administration during breastfeeding if possible. Safety in pediatric patients has not been established, so it should be used cautiously in children. Elderly patients may have reduced body functions, so dosing should be adjusted appropriately. In cases of overdose, administration should be stopped immediately, a low-calcium diet should be implemented, and blood calcium levels should be checked frequently. Dialysis or pharmacological treatment may be necessary according to need. Before administration, check for any abnormalities in the injection solution, do not mix with other medications, and use promptly after opening, disposing of any remaining medication.
Side effects
- Anaphylaxis
- localized redness at the injection site
- mild pain
- dry mouth
- nausea
- vomiting
- dry throat
- constipation
- metallic taste
- loss of appetite
Show 67 moreCollapse
- pancreatitis
- abdominal cramps
- headache
- drowsiness
- insomnia
- numbness in the hands
- dizziness
- altered consciousness
- vertigo
- worsening of depression
- agitation
- anxiety
- psychotic disorder
- hypertension
- deep vein thrombosis
- palpitations
- QT interval prolongation
- atrioventricular block
- atrial fibrillation
- bone pain
- joint pain
- runny nose
- elevated AST
- elevated ALT
- elevated LDH
- elevated GGTP
- elevated BUN
- itching
- acne
- conjunctivitis
- photophobia
- conjunctival congestion
- weakness
- myalgia
- limb pain
- polyuria
- nocturia
- weight loss
- high fever
- decreased libido
- proteinuria
- hypercholesterolemia
- dystrophic calcification
- elevated serum phosphorus levels
- elevated serum calcium
- malaise
- decreased muscle strength
- facial flushing
- dysphoria
- abdominal pain
- chest tightness
- eosinophilia
- lymphocytopenia
- lymphocytosis
- elevated hematocrit
- neutrophilia
- monocytosis
- thrombocytopenia
- increased hemoglobin
- elevated liver transaminases
- elevated ALP
- hypercalciuria
- hypermagnesemia
- hyperphosphatemia
- systemic vascular calcification
- nephrocalcinosis
- and calcification of other soft tissues
Not everyone experiences these, and they can vary from person to person.
Storage
This drug may be sensitive to light, so it should be stored in a light-tight sealed container. It is also advisable to store the drug at room temperature, meaning at a generally comfortable indoor temperature that is neither too hot nor too cold.
Appearance and packaging
Appearance
A brown ampoule injection containing a colorless to pale yellow transparent liquid
Package unit
10 ampoules (1 mL/ampoule x 10)
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.